About (3SBI) 3SBio Inc.

Company Background

3SBio Inc., symbol 3SBI (TRADU:3SBI), is a leading biotechnology company based in Shenyang, China, specializing in the research, development, manufacturing, and commercialization of biopharmaceutical products. Founded in 1993, 3SBio focuses on innovative therapies in oncology, nephrology, dermatology, and autoimmune diseases. The company has built a robust product portfolio that includes recombinant proteins, monoclonal antibodies, and other biologic drugs addressing significant unmet medical needs. With vertically integrated operations covering R&D, production, and distribution, 3SBio is dedicated to advancing high-quality, affordable biologics to improve patient outcomes both in China and globally.

Market Position

3SBio holds a strong position in China’s biopharmaceutical industry as one of the country’s earliest and most successful biologics developers. The company is recognized for its leadership in recombinant protein drugs, particularly erythropoietin (EPO) and other hematology-related therapies. Through its extensive research platform and strategic collaborations with global pharmaceutical firms, 3SBio continues to expand its therapeutic pipeline in oncology, dermatology, and autoimmune treatments. Its advanced biomanufacturing capabilities—compliant with global Good Manufacturing Practice (GMP) standards—enable large-scale production and international distribution. The company’s growing presence in overseas markets, supported by a strong intellectual property portfolio and expanding clinical programs, positions it among China’s most globally competitive biopharma enterprises.

Key Financial and Industry Highlights

3SBio demonstrates steady financial performance driven by strong sales of its core biologics, consistent R&D investment, and expanding product commercialization. The company’s diversified revenue base includes both proprietary and licensed biologic products, providing resilience against market fluctuations. Ongoing advancements in biosimilars, antibody-drug conjugates (ADCs), and targeted cancer therapies underscore 3SBio’s commitment to innovation. The firm also continues to invest in digital transformation and global partnerships to enhance its R&D efficiency and accelerate clinical development.

As China’s biopharmaceutical sector continues to grow rapidly, 3SBio is well-positioned to capitalize on rising healthcare demand and government support for domestic innovation. Its focus on sustainable growth, scientific excellence, and patient-centered innovation ensures a strong foundation for long-term success. With a proven track record in biologics development and commercialization, 3SBio Inc. remains a key player in shaping the future of biotechnology and precision medicine in China and worldwide.